Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 16/20 | 0.77 |
| ▸ | BCL2 | P10415 | 7/20 | 0.73 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.73 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420193 | 0.98 | BCL2L1 (0.74) | BCL2L1BCL2MCL1BCL2A1MEN1 | |
| SCHEMBL353018 | 0.87 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL353312 | 0.86 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL19420195 | 0.85 | BCL2L1 (0.95) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL14922857 | 0.85 | BCL2L1 (0.84) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL353855 | 0.85 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL10112868 | 0.82 | BCL2L1 (0.95) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL10113185 | 0.81 | BCL2L1 (0.90) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL19425625 | 0.81 | BCL2L1 (0.90) | BCL2L1BCL2MCL1BCL2A1BAK1 | |
| SCHEMBL354745 | 0.77 | BCL2L1 (1.00) | BCL2L1BCL2MCL1BCL2A1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | BCL2L1 953/4885BCL2 520/4885MCL1 137/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | BCL2L1 464/4885BCL2 132/4885MCL1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.